Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
Jonathan W. Riess(University of California Davis Medical Center), Darren A.E. Cross(AstraZeneca (United Kingdom)), Anna D. Staniszewska(AstraZeneca (United Kingdom)), Ludovic Ménard(AstraZeneca (United Kingdom)), Nicolas Floc’h(AstraZeneca (United Kingdom)), Maria Emanuela Cuomo(AstraZeneca (United Kingdom)), James Keck(Jackson Laboratory), David R. Gandara(University of California, Davis), Darren McKerrecher(AstraZeneca (United Kingdom)), Rebekah A. Tsai(University of California, Davis), Matthew W. Martin(Amgen (United States)), Jonathon P. Orme(AstraZeneca (United Kingdom)), Mingshan Cheng(Jackson Laboratory), Raymond Finlay(AstraZeneca (United Kingdom)), Richard A. Ward(AstraZeneca (Poland)), Chunting Ye(Jackson Laboratory), Daniel P. Vang(University of California, Davis), Daniel O’Neill(AstraZeneca (United Kingdom)), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 8
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k